Journal article

Why Calls for More Routine Carotid Stenting Are Currently Inappropriate An International, Multispecialty, Expert Review and Position Statement

Anne L Abbott, Mark A Adelman, Andrei V Alexandrov, P Alan Barber, Henry JM Barnett, Jonathan Beard, Peter Bell, Martin Bjorck, David Blacker, Leo H Bonati, Martin M Brown, Clifford J Buckley, Richard P Cambria, John E Castaldo, Anthony J Comerota, E Sander Connolly, Ronald L Dalman, Alun H Davies, Hans-Henning Eckstein, Rishad Faruqi Show all

STROKE | LIPPINCOTT WILLIAMS & WILKINS | Published : 2013

University of Melbourne Researchers

Grants

Awarded by Australian National Health and Medical Research Council Fellowship


Awarded by MRC


Awarded by Medical Research Council


Awarded by National Institute for Health Research


Funding Acknowledgements

Anne Abbott's time on this project was partially supported by an Australian National Health and Medical Research Council Fellowship (ID: 472700) and supported in part by the Victorian Government's OIS Program.Henry Barnett was PI of the North American Symptomatic Carotid Endarterectomy Trial (NASCET). Jonathan Beard is on the Steering Committee of the International Carotid Stenting Study (ICSS). David Blacker has received sponsorship to scientific meetings from Boehringer Ingelheim. He has previously been a member of the advisory board for NovoNorsdisk (regarding Factor VII) and receives funding for involvement in the Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin With Terutroban in Patients With a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study. Leo Bonati is a member of the ICSS Study Group, a member of the Steering Committee of the European Carotid Surgery Trial 2 (ECST-2) and the coordinating member of the Steering Committee of the Carotid Stenting Trialists Collaboration (CSTC). Prof Martin Brown is the Chief Investigator of the Carotid and Vertebral Transluminal Angioplasty Study (CAVATAS), ICSS, and the ECST-2. Richard Cambria is co-PI for a future transcervical carotid stenting/flow reversal trial (ROADSTER). Anthony Comerota received research funding for the Jobst Vascular Institute to participate in the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST). Ronald Dalman previously served as site PI for the Abbott Industries Protected Carotid Artery Stenting in Patients at High Risk for Carotid Endarterectomy (PROTECT) trial for California and is a co-holder of a provisional patent for a carotid distal protection device. Alun Davies receives funding from the Stroke Association on the evaluation of carotid plaque. Hans-Henning Eckstein is co-PI of the Stent-Supported Percutaneous Angioplasty of the Carotid Artery versus Endarterectomy (SPACE-2) Study. He was a member of the Steering Committee of the SPACE-1 Study. Gustav Fraedrich is member of the steering committee of the Carotid Stenting Trialists Collaboration (CSTC) and member of the steering committee of the SPACE-2-Study. He was a member of the Writing Committee of the SPACE-1 Study. Graeme Hankey was a member of the ECST Collaborative Group and the NASCET Collaborators. Michael Hennerici founded the European Stroke Conference: http://www.eurostroke.eu. He is a principal investigator, coordinator, and board member for several international clinical trials including the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events Trial (CAPRIE), Aspirin and Clopidogrel Compared With Clopidogrel Alone After Recent Ischemic Stroke or Transient Ischemic Attack in High-Risk Patients Trial (MATCH), Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial (SPARCL), SPACE-1, and SPACE 2. Dimitri Mikhailidis has given talks and attended conferences sponsored by Merck, Sharp and Dohme, Genzyme, and Abbott Industries. Wesley Moore is a co-PI for the CREST and member of the CREST Executive Committee. Peter A. Ringleb is the Clinical coordinator of SPACE-1, a member of the steering committee of SPACE-2 and a member of the guideline-committee of the German Neurological Society, German Stroke Society, and European Stroke Organization. Peter Rothwell is on the Data Monitoring Committee of the SPACE-2 trial. He is Chair of the End point Adjudication Committee of the Asymptomatic Carotid Artery Surgery Trial-2 (ACST-2). He is on the Steering Committee of the ECST-2 and the General Anesthetic versus Local Anesthetic (GALA) for Carotid Surgery Trial. Peter Sandercock is the independent chair of the MRC/NIHR ACST-2 Trial. J.David Spence has received lecture fees or consulting fees from Merck, Novartis and Boehringer-Ingelheim and sponsorship to scientific meetings from Boehringer-Ingelheim. He obtains research funding from the Canadian Institutes of Health Research, the Heart and Stroke Foundation of Canada (Ontario), and the National Institutes of Health. Ankur Thapar receives research funding from the Royal College of Surgeons of England. Wei Zhou receives research funding from the National Institute of Health/National Institute of Neurological Disorders and Stroke for evaluating outcomes of carotid interventions. The other authors have no conflicts to report.